Literature DB >> 28940845

Emerging roles of syndecan 2 in epithelial and mesenchymal cancer progression.

Maria Mytilinaiou1, Dragana Nikitovic1, Aikaterini Berdiaki1, Antonis Kostouras1, Antonis Papoutsidakis1, Aristidis M Tsatsakis2, George N Tzanakakis1.   

Abstract

Syndecan 2 (SDC2) belongs to a four-member family of evolutionary conserved small type I transmembrane proteoglycans consisting of a protein core to which glycosaminoglycan chains are covalently attached. SDC2 is a cell surface heparan sulfate proteoglycan, which is increasingly drawing attention for its distinct characteristics and its participation in numerous cell functions, including those related to carcinogenesis. Increasing evidence suggests that the role of SDC2 in cancer pathogenesis is dependent on cancer tissue origin rendering its use as a biomarker/therapeutic target feasible. This mini review discusses the mechanisms, through which SDC2, in a distinct manner, modulates complex signalling networks to affect cancer progression.
© 2017 IUBMB Life, 69(11):824-833, 2017. © 2017 International Union of Biochemistry and Molecular Biology.

Entities:  

Keywords:  cancer biology; glycobiology; proteoglycans; syndecan

Mesh:

Substances:

Year:  2017        PMID: 28940845     DOI: 10.1002/iub.1678

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  18 in total

1.  Examination of Genetic Susceptibility in Radiation-Associated Meningioma.

Authors:  A Pemov; J Kim; K Jones; A Vogt; S Sadetzki; D R Stewart
Journal:  Radiat Res       Date:  2022-07-01       Impact factor: 3.372

2.  miR-218 affects the ECM composition and cell biomechanical properties of glioblastoma cells.

Authors:  Małgorzata Grabowska; Konrad Kuczyński; Monika Piwecka; Alicja Rabiasz; Joanna Zemła; Paweł Głodowicz; Dariusz Wawrzyniak; Małgorzata Lekka; Katarzyna Rolle
Journal:  J Cell Mol Med       Date:  2022-06-15       Impact factor: 5.295

3.  Biglycan Regulates MG63 Osteosarcoma Cell Growth Through a LPR6/β-Catenin/IGFR-IR Signaling Axis.

Authors:  John Aggelidakis; Aikaterini Berdiaki; Dragana Nikitovic; Antonis Papoutsidakis; Dionysios J Papachristou; Aristidis M Tsatsakis; George N Tzanakakis
Journal:  Front Oncol       Date:  2018-10-23       Impact factor: 6.244

Review 4.  Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression.

Authors:  Arvindhan Nagarajan; Parmanand Malvi; Narendra Wajapeyee
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-24       Impact factor: 5.555

Review 5.  Proteoglycans and Immunobiology of Cancer-Therapeutic Implications.

Authors:  George Tzanakakis; Monica Neagu; Aristidis Tsatsakis; Dragana Nikitovic
Journal:  Front Immunol       Date:  2019-04-24       Impact factor: 7.561

Review 6.  Heparan Sulfate Glycosaminoglycans: (Un)Expected Allies in Cancer Clinical Management.

Authors:  Isabel Faria-Ramos; Juliana Poças; Catarina Marques; João Santos-Antunes; Guilherme Macedo; Celso A Reis; Ana Magalhães
Journal:  Biomolecules       Date:  2021-01-21

Review 7.  Proteoglycans as Mediators of Cancer Tissue Mechanics.

Authors:  Anna Barkovskaya; Alexander Buffone; Martin Žídek; Valerie M Weaver
Journal:  Front Cell Dev Biol       Date:  2020-11-30

8.  SDC2 and TFPI2 Methylation in Stool Samples as an Integrated Biomarker for Early Detection of Colorectal Cancer.

Authors:  Weisong Zhang; Chaogang Yang; Shuyi Wang; Zhenxian Xiang; Rongzhang Dou; Zaihuan Lin; Jinsen Zheng; Bin Xiong
Journal:  Cancer Manag Res       Date:  2021-04-30       Impact factor: 3.602

Review 9.  Proteoglycans-Biomarkers and Targets in Cancer Therapy.

Authors:  Dragana Nikitovic; Aikaterini Berdiaki; Ioanna Spyridaki; Theodoros Krasanakis; Aristidis Tsatsakis; George N Tzanakakis
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-06       Impact factor: 5.555

Review 10.  Heparan Sulfate Proteoglycan Signaling in Tumor Microenvironment.

Authors:  Valeria De Pasquale; Luigi Michele Pavone
Journal:  Int J Mol Sci       Date:  2020-09-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.